NKNajm S. Khan

Najm S. Khan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Najm S. Khan has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Trends of Adjuvant Radiation After TORS in Clinically Node Negative Oropharyngeal Cancer

    by Najm S. Khan, Craig A. Bollig

    Objective: Frequency of adjuvant treatment for clinically node negative (cN0) oropharyngeal cancer (OPC) patients, candidates for single modality treatment, is not well established. We aimed to determine the rate and clinical predictors of adjuvant radiation therapy (aRT) among cT1–T2 N0 patients undergoing transoral robotic surgery (TORS). Methods: The National Cancer Database was retrospectively reviewed for cT1–T2 N0 OPC patients who received TORS as definitive treatment between 2010 and 2017. Demographic, oncologic data, and the proportion of patients receiving aRT were collected. Multivariable logistic regression was performed to determine clinical predictors of aRT. Adjusted Odds Ratios (aOR) with 95% Confidence Intervals (95% CI) were calculated. Results: 1173 cN0 OPC patients underwent TORS (mean age 62 ± 9 years). 95% of patients were pT1–T2 and 59% were pN0. Overall, 29% of patients received aRT, including 21% of cT1 patients and 37% of cT2 patients. 32% of patients with tonsil/lateral pharyngeal wall and 29% with base of tongue tumors received aRT. Among those with negative margins, 25% received aRT. Positive margins (aOR 4.0, 95% CI 2.7–5.8), base of tongue subsite (aOR 2.7, 95% CI 1.5–4.7), and salivary gland malignancies (aOR 2.9, 95% CI 1.6–5.3) had an increased likelihood of adjuvant RT. Compared to pT1 patients, pT2 was associated with receiving adjuvant RT (aOR 1.9, 95% CI 1.4–2.6). HPV status was not a significant predictor of aRT. Conclusion: Nationally, most cT1–T2 N0 OPC patients undergoing TORS ultimately do not receive adjuvant radiation therapy, thus representing excellent candidates for single‐modality treatment in most cases. Level of Evidence: N/A.

  • A systematic evaluation of clinical practice guidelines for the treatment and management of vestibular schwannoma

    by Najm S. Khan, Samantha M. Shave, Josephine Alegun, Jonathan P. Kuriakose, Phillip Ashley Wackym, Scott B. Shapiro

    Systematically appraise the quality of clinical practice guidelines (CPGs) for vestibular schwannoma treatment and management by utilizing the Appraisal of Guidelines for Research and Evaluation (AGREE II) instrument. A systematic search of CPGs for the treatment and management of vestibular schwannoma was conducted. MEDLINE (PubMed), EMBASE, and Scopus were queried from inception to January 2023. Inclusion criteria was national and international guidelines or consensus statements. Data was extracted from included articles and four reviewers independently evaluated guidelines in the 6 domains of the AGREE II tool. A domain score was generated with a satisfactory threshold being ≥ 60%. 785 articles were screened with 9 CPGs selected for evaluation. Three CPGs were found to be "high" quality, five "average" quality, and one "low" quality. CPGs overall scored highest in the "Scope and Purpose" (domain score: 93.67 ± 7.58) and "Clarity and Presentation" (89.04 ± 13.13), while "Applicability" (40.86 ± 25.27) and "Stakeholder Involvement" (57.56 ± 22.08) had the lowest scores. The level of agreement between reviewers was high, with intraclass correlation coefficients ranging from 0.91-0.98 across domains. This appraisal demonstrated an average to high quality for most CPGs regarding vestibular schwannoma treatment and management. While these findings suggest most CPGs are at least average quality, there are opportunities for improvement in several aspects, particularly in domains of applicability, clarifying of conflicts of interest, strength of methodology, and stakeholder involvement.


  • Open Access

    Outcomes of Mobile Health Use in Sinonasal Surgery: A Retrospective Cohort Study (Preprint)

    by Heli Majeethia, Akshay R. Prabhakar, Justina R. Varghese, Najm S. Khan, Roshan Dongre, Vincent Provasek, Faizaan I. Khan, Zain Mehdi, Omar G. Ahmed, Masayoshi Takashima

    Background: Mobile health (mHealth) technologies are increasingly integrated into perioperative care to enhance patient engagement and communication. Prior studies in surgical and medical specialties suggest that mHealth platforms may be associated with reductions in hospital stay and readmissions; however, evidence supporting their impact in otolaryngology, particularly in sinonasal surgery, remains limited. Objective: The aim of this study was to evaluate the association between perioperative enrollment in CareSense, a patient-facing mHealth platform, and postoperative health care utilization outcomes, including hospital readmissions, emergency department (ED) visits, and length of stay (LOS), among adults undergoing sinonasal surgery. Methods: This is a retrospective cohort study performed at a single tertiary care academic medical center between May 2021 and January 2024. All adult patients (≥18 years) who underwent sinonasal surgery with two fellowship-trained rhinologists during the study period were included. CareSense was offered to all patients at the time of surgical scheduling, and enrollment was voluntary. Patients were categorized into CareSense participants and nonparticipants. Primary outcomes were all-cause hospital readmissions and ED visits within 30, 60, and 90 days following surgery. Secondary outcomes included the length of hospital stay among readmitted patients. Clinical, demographic, and outcome data were obtained through retrospective electronic health record review. Univariate analyses compared outcomes between groups, and multivariable logistic regression using generalized estimating equations was performed to estimate the association between CareSense participation and outcomes while adjusting for age, sex, hypertension, and diabetes. Results: A total of 1135 patients were included, of whom 340 (30%) enrolled in CareSense and 795 (70%) did not. Compared with nonparticipants, CareSense participants had lower adjusted odds ratio (OR) for readmission for any cause at 30 days (OR 0.24, 95% CI 0.08‐0.75; P =.007), 60 days (OR 0.40, 95% CI 0.19‐0.83; P =.01), and 90 days (OR 0.54, 95% CI 0.29‐0.99; P =.04). Among patients who were readmitted, mean LOS was shorter in the CareSense group than in the nonparticipating group (0.17 vs 1.68 d; P <.001). The majority of readmissions in both cohorts were unrelated to complications of the index sinonasal procedure. Conclusions: This study demonstrates the benefit of CareSense in lowering postoperative readmission rates and LOS for sinonasal surgery patients, illustrating the role of medical health technology in improving patient care and quality outcomes. Perioperative enrollment in a patient-facing mHealth platform was associated with lower postoperative health care utilization and shorter hospital length of stay following sinonasal surgery. Given the voluntary nature of enrollment and the observational design, these findings should be interpreted as observation findings and hypothesis-generating for prospective studies to more definitively assess the causal impact of mHealth interventions and to identify which components of digital perioperative care most effectively improve outcomes in otolaryngologic surgery.

  • Open Access

    Outcomes of Mobile Health Use in Sinonasal Surgery: A Retrospective Cohort Study (Preprint)

    by Heli Majeethia, Najm S. Khan, Roshan Dongre, Vincent Provasek, Faizaan I. Khan, Zain Mehdi, Omar G. Ahmed, Masayoshi Takashima

    BACKGROUND Mobile health (mHealth) technologies are increasingly being utilized for patient care, but literature supporting their efficacy in otolaryngology is limited. OBJECTIVE This study seeks to understand the impact that CareSense, an mHealth technology designed to educate patients on their upcoming surgeries, utilization has on post-operative outcomes of sinonasal surgery. METHODS This is a retrospective cohort study performed at a single tertiary care academic medical center between May 2021 and January 2024. A total of 1,135 patients underwent surgery between May 2021 and January 2024, with 340 CareSense participants and 795 nonparticipants. The outcomes measured were readmission rates and emergency room visits at 30, 60, and 90 days post-surgery, as well as length of stay (LOS) in the event of readmission. Univariate and multivariate analyses with logistic regression were performed, with a p-value < 0.05 considered significant. RESULTS The participating group had a lower adjusted odds ratio (OR) for readmission for any cause at 30 days (OR 0.24, CI95% 0.08 – 0.75; P = .007), 60 days (OR 0.4, CI95% 0.19 – 0.83; P = .013), and 90 days (OR 0.54, CI95% 0.29 – 0.99; P = .04) when compared to the nonparticipating group. The average LOS for readmissions for the participating group was 0.17 days compared to 1.68 days in the nonparticipating group (P < .001). CONCLUSIONS This study demonstrates the benefit of CareSense in lowering postoperative readmission rates and LOS for sinonasal surgery patients, illustrating the role of medical health technology in improving patient care and quality outcomes.

  • Private Equity in Otolaryngology: What Is the Impact on Medicare Payments?

    by Roshan Dongre, Najm S. Khan, Faizaan Khan, Keyvon Rashidi, Heli Majeethia, Isuru Somawardana, Jeffrey T. Vrabec, Masayoshi Takashima, Omar G. Ahmed

    Objective: This study aims to assess whether private equity (PE) acquisitions of otolaryngology–head and neck surgery (OHNS) practices are associated with changes in Medicare payments and procedure volume.Study Design: A cross‐sectional study.Setting: PitchBook and the Medicare Provider Utilization and Payment Data File.Methods: PE acquisitions of OHNS practices were determined using the PitchBook database and linked to the 2016‐2022 Medicare Provider Utilization and Payment Data File based on practice address. Non‐PE practices were included as control if located in a state where an acquisition occurred, with the index point corresponding to the year of acquisition. Medicare payments for all procedures were totaled and averaged. PE‐affiliated and non‐PE‐affiliated practices were compared before and after the acquisition.Results: A total of 9 acquisitions of OHNS practices across 7 states were identified. Pre‐acquisition, PE‐affiliated otolaryngologists performed more procedures per year (1289 vs 1006, P < .001) compared to their non‐PE counterparts, with average payments per procedure of $92.8 versus $91.36 (P = .398), respectively. Post‐acquisition, PE‐affiliated otolaryngologists performed more procedures per year (1166 procedures vs 950, P = .015) compared to their non‐PE counterparts, with average payments of $105.2 versus $91.3 (P < .001), respectively.Conclusion: PE‐acquired OHNS practices had increases in average Medicare payments per procedure after acquisition with minimal changes in procedure volumes. In addition, PE firms had a greater number of procedures in both periods. This finding suggests that PE may emphasize both performing high‐payout procedures and investing in high‐volume practices, although this can be firm‐dependent.


  • Open Access

    Pediatric Adenotonsillectomy Opioid Prescriptions Before and After Practice Guidelines and American Academy of Pediatrics Challenge

    by Najm S. Khan, David Z. Allen, Yin Yiu, Omar G. Ahmed, Masayoshi Takashima, Zi Y. Jiang

    The opioid epidemic continues to concern the CDC and public health officials but recent trends in opioid prescribing rates following common pediatric otolaryngology surgeries are unexplored. This retrospective cohort study queried the TriNetX Research database from January 1, 2010, through December 31, 2023, for pediatric patients who underwent tonsillectomy and/or adenoidectomy and received oral opioids within 5 days of surgery. Prescription trends from 2010 to 2017 were compared to 2022 to 2023, after the publication of multiple clinical practice guidelines (CPGs). Of 286,572 surgeries, 29% of patients received postoperative opioids. Comparing the 2 time periods, a significant decrease was observed in the risk of postoperative opioid prescriptions following 2022 (RR 0.87, CI95% 0.86‐0.88). Prescribing rates decreased between 2018 and 2023 from 34% to 24%. Publication of CPGs were associated with a decrease in opioid prescribing rates and may have contributed to an encouraging trend in opioid stewardship.


  • Posterior Nasal Nerve Ablation as a Viable Treatment Option for the Primary Symptom of Postnasal Drip

    by Aatin K. Dhanda, Daniel Gorelik, Najm Khan, Masayoshi Takashima, Patrick Bishara, Edward D. McCoul, Aria Jafari, Omar G. Ahmed

    Background: Postnasal drip (PND) syndrome is a prevalent complaint encountered in otolaryngology practices. PND may be refractory to medical therapy, and surgical treatments are complicated by side effects. Objective: While posterior nasal nerve (PNN) ablation has demonstrated efficacy for chronic rhinitis overall, we sought to examine the effect of PNN ablation for patients with PND as their primary complaint. Methods: This is a retrospective case series study of 40 chronic rhinitis (CR) patients with a primary complaint of PND. Included patients had to have failed medical therapy such as anti-cholinergic nasal sprays, reflux treatments, and/or nasal steroids. Primary outcome measures included 22 item Sino-Nasal Outcome Test (SNOT-22) PND component and Total Nasal Symptom Score. Secondary outcome measure was subjective improvement, defined as a > 30% improvement in PND symptoms. Results: Median follow-up was 138 days (interquartile range: 72-193). 72.5% (29/40) of patients reported at least a 30% improvement in PND symptoms. Mean PND SNOT-22 scores were 4.2/5 (SD = 0.8) pre-procedure versus 1.9/5 (SD = 1.3) post-procedure ( P = .001). PNN ablation response did not correlate to ipratropium bromide nasal spray response, although younger and non-smoker patients had better response rates. Conclusion: This exploratory study of PNN ablation for the primary symptom of PND demonstrates efficacy as assessed by the PND component of SNOT-22 and subjective improvement. These results can be useful in guiding physician–patient discussions in determining treatment options for medically refractory PND.


  • Appraisal of clinical practice guidelines for salivary gland cancer management utilizing AGREE II instrument

    by Kaiwen Chen, Young Lee, Jonathan P. Kuriakose, Najm S. Khan, Alvaro Moreira, Karthik Rajasekaran


  • Multi-Institutional Analysis of Insurance Denial Patterns Within Rhinology

    by Tyler A. Janz, Najm S. Khan, Aatin K. Dhanda, Masayoshi Takashima, Arthur W. Wu, Dennis M. Tang, Thomas S. Higgins, Murugappan Ramanathan, Omar G. Ahmed

    Background: Obtaining insurance approval is a necessary component of healthcare in the United States and denials of these claims have been estimated to result in a loss of 3% to 5% of revenue. Objective: Examine the trends in insurance denials for rhinological procedures. Methods: A retrospective review of deidentified financial data of patients who were treated by participating physicians across 3 institutions from January 1, 2021, to June 30, 2023. The data was queried for rhinological and non-rhinological procedures via CPT codes. Cumulative insurance denials were calculated and stratified by procedure and insurance type. Write-offs were dollar amounts associated with final denials. Results: A sample of 102,984 procedures and visits revealed a final denial rate between 2.2% and 2.9% across institutions ( p = .72). The top three rhinological procedures for final write-offs were: nasal endoscopy (16.24%, $111,836.87), nasal debridement or polypectomy (6.48%, $79,457.51), and destruction of intranasal lesion (2.11%, $56,932.20). The write-off percentage for each procedure was highest among commercial insurance payers as opposed to Medicare or Medicaid. Conclusion: Final denial rates of rhinology procedures ranged between 2% and 3%. Common procedures such as nasal endoscopy and nasal debridement are among the highest written-off procedures. Insurance denials can lead to notable revenue loss. Rhinology practices must continue to remain knowledgeable of the changes and effects of insurance reimbursement on their practice.


  • Perceptions and Understanding of Transgender Patient Care: A Survey of Practicing Facial Plastic Surgeons

    by Megan L. Swonke, Anthony E. Brissett, Najm S. Khan, Joshua J. Kain, Fred J. Bressler, Amina I. Malik, Tariq A. Syed, Angela K. Sturm

    Transgender individuals face significant health disparities including deficiencies in physician education, knowledge, and comfort with care. The objective of this study was to determine the perceptions, practice patterns, and familiarity of facial plastic surgeons with transgender health care. An anonymous questionnaire was sent to facial plastic surgeons within the American Academy of Facial Plastic and Reconstructive Surgery list-serve. Primary datapoints included participant characteristics, transgender-related experience, and educational goals. Of the 66 facial plastic surgeons surveyed, 49% had treated 1 to 10 transgender patients during their career, and 70% were actively treating at least 1 transgender patient. The number of patients treated and surgeries performed was significantly associated with self-perceived competence, comfort counseling on gender-affirming surgeries, discussing gender identity, asking preferred pronouns, and a desire to learn more about transgender care. Most participants (61%) obtained transgender care training through real-world experience, with only 18% receiving formal training in residency or fellowship. In total, 50% of respondents believe transgender care training among facial plastic surgeons is inadequate and 60% support its incorporation into residency/fellowship curricula. Increased awareness is needed to address the disparities experienced by transgender patients. Many facial plastic surgeons desire to learn more and support incorporating transgender care into training. Understanding the current state of transgender care can assist the facial plastic community in promoting education that strengthens physicians' ability to deliver competent care that addresses the inequities faced by this diverse group.